And New Blood Clot Side Effect Lawsuits, Including Some Involving The Lesser-Known Safyral And Beyaz DRSP Pills, Are Still Being Filed Against Bayer
SUMMARY: From Bayer’s Stockholders’ Newsletter Financial Report as of September 30, 2014, published on October 30, 2014:
As of October 13, 2014, Bayer had reached agreements, without admission of liability, to settle the claims of approximately 9,200 claimants in the U.S. for a total amount of about US$1.8 billion. Bayer has only been settling claims in the U.S. for venous clot injuries (deep vein thrombosis or pulmonary embolism) after a case-specific analysis of medical records on a rolling basis. Such injuries are alleged by about 2,100 of the pending unsettled claimants. Bayer will continue to consider the option of settling such individual lawsuits in the U.S. on a case-by-case basis.
To put all of this into context, the YAZ / Yasmin litigation began back in mid-2009 when the first lawsuits against Bayer were filed. In January 2012 Bayer decided to begin to attempt to negotiate settlements for YAZ / Yasmin / Ocella / Gianvi blood clot lawsuits, e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE), on a case-by-case basis. And new lawsuits, including some cases involving Safyral and Beyaz, are still being filed against Bayer to date.[Read this article in full at original source]
Strictly Confidential, No Obligation.